In a study of 500 patients in the US with metastatic cancer, survival doubled from just over six months to more than 13 months compared with patients who received chemotherapy, reports Dagens Medicin.
"I'm happy about this. The survival advantage is very large, considering how difficult this disease is to treat," Daniel Öhlund, oncologist and chief physician at Norrland University Hospital in Umeå, told the newspaper.
"It is also the first time we have a drug that is more effective than chemotherapy in broad patient groups."
The drug, daraoxanrasib, inhibits a protein that drives tumor development in most cases.
